Allogenic dendritic cell and tumor cell fused vaccine for targeted imaging and enhanced immunotherapeutic efficacy of gastric cancer

Biomaterials

Volumn 54, Issue , 2015, Pages 177-187

  Li, Chao ^a   Liang, Shujing ^b   Zhang, Chunlei ^a   Liu, Yanlei ^a   Yang, Meng ^a   Zhang, Jingpu ^a   Zhi, Xiao ^a   Pan, Fei ^a   Cui, Daxiang ^a,c  

^a Shanghai Jiao Tong University   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Fusion cell; Gastric cancer; Immunotherapy; Targeted imaging; Vaccine

Indexed keywords

CYTOLOGY; DISEASES; INFRARED DEVICES; MAMMALS; SEMICONDUCTOR QUANTUM DOTS; TUMORS; VACCINES;

ANIMAL IMAGING SYSTEMS; CLINICAL APPLICATION; DENDRITIC CELLS (DCS); GASTRIC CANCERS; IMMUNOTHERAPY; NEAR INFRARED REGION; POTENTIAL MECHANISM; TARGETED IMAGING;

CELLS;

ALLOGENIC DENDRITIC CELL TUMOR CELL FUSED VACCINE; CANCER VACCINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; MACROGOL; QUANTUM DOT; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL IMAGING SYSTEM; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER PROGNOSIS; CARCINOGENICITY; CELL ISOLATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOPROPHYLAXIS; IN VIVO STUDY; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY MECHANISM; STOMACH CANCER; TARGET CELL; TUMOR GROWTH; VACCINATION; ANIMAL; C57BL MOUSE; DENDRITIC CELL; FLUORESCENCE MICROSCOPY; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; STOMACH NEOPLASMS; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALIA; MUS;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DENDRITIC CELLS; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; QUANTUM DOTS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84928014277     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.03.024     Document Type: Article

References (45)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. Ca - Cancer J Clin 2014, 64:9-29.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Takahashi T., Saikawa Y., Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers 2013, 5:48-63.
4. Compare D., Rocco A., Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharm 2010, 14:302-308.
5. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. JExp Med 2011, 208:1989-2003.
6. Fuertes M.B., Kacha A.K., Kline J., Woo S.-R., Kranz D.M., Murphy K.M., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. JExp Med 2011, 208:2005-2016.
7. Tan C., Dannull J., Nair S.K., Ding E., Tyler D.S., Pruitt S.K., et al. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. JSurg Res 2013, 185:904-911.
8. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12:265-277.
9. Du Y.C., Lin P., Zhang J., Lu Y.R., Ning Q.Z., Wang Q. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Tissue Antigens 2006, 67:368-376.
10. Jahnisch H., Fussel S., Kiessling A., Wehner R., Zastrow S., Bachmann M., et al. Dendritic cell-based immunotherapy for prostate Cancer. Clin Dev Immunol 2010, 2010:1-8.
11. Benencia F., Courreges M.C., Coukos G. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. JTransl Med 2008, 6.
12. Chen X., Liu Z., Huang Y., Li R., Zhang H., Dong S., et al. Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma. Autoimmunity 2014, 47:46-56.
13. Cicchelero L., de Rooster H., Sanders N.N. Various ways to improve whole cancer cell vaccines. Expert Rev Vaccines 2014, 13:721-735.
14. Rosenblatt J., Vasir B., Uhl L., Blotta S., MacNamara C., Somaiya P., et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011, 117:393-402.
15. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., McKenna E.A., Yanik G.A., Levine J.E., et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001, 61:8513-8519.
16. Noguchi T., Kato T., Wang L.N., Maeda Y., Ikeda H., Sato E., et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res 2012, 72:1672-1682.
17. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest 2003, 21:873-886.
18. Foda M.F., Huang L., Shao F., Han H. Biocompatible and highly-luminescent near infrared CuInS2/ZnS quantum dots embedded silica beads for cancer cell imaging. Acs Appl Mater Interfaces 2014, 6:2011-2017.
19. Li L., Daou T.J., Texier I., Kim Chi T.T., Liem N.Q., Reiss P. Highly luminescent CuInS2/ZnS core/shell nanocrystals: cadmium-free quantum dots for invivo imaging. Chem Mater 2009, 21:2422-2429.
20. Cassette E., Pons T., Bouet C., Helle M., Bezdetnaya L., Marchal F., et al. Synthesis and characterization of near-infrared Cu- In- Se/ZnS core/shell quantum dots for invivo imaging. Chem Mater 2010, 22:6117-6124.
21. Pons T., Pic E., Lequeux N., Cassette E., Bezdetnaya L., Guillemin F., et al. Cadmium-free CuInS2/ZnS quantum dots for sentinel lymph node imaging with reduced. ACS Nano 2010, 4:2531-2538.
22. Dunnion D., Cywinski A., Tucker V., Murray A., Rickinson A., Coulie P., et al. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells invitro. Immunology 1999, 98:541-550.
23. Kawada M., Ikeda H., Takahashi T., Ishizu A., Ishikura H., Katoh H., et al. Vaccination of fusion cells of rat dendritic and carcinoma cells prevents tumor growth invivo. Int J Cancer 2003, 105:520-526.
24. Park J., Kim S.-W. CuInS2/ZnS core/shell quantum dots by cation exchange and their blue-shifted photoluminescence. JMater Chem 2011, 21:3745-3750.
25. Li C., Ji Y., Wang C., Liang S., Pan F., Zhang C., et al. BRCAA1 antibody-and Her2 antibody-conjugated amphiphilic polymer engineered CdSe/ZnS quantum dots for targeted imaging of gastric cancer. Nanoscale Res Lett 2014, 9:244.
26. Jung S., Unutmaz D., Wong P., Sano G.-I., De los Santos K., Sparwasser T., et al. Invivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 2002, 17:211-220.
27. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. JExp Med 1995, 182:389-400.
28. Randolph G.J., Beaulieu S., Lebecque S., Steinman R.M., Muller W.A. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998, 282:480-483.
29. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
30. Zhou L.-J., Tedder T.F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. JImmunol 1995, 154:3821-3835.
31. Prechtel A.T., Steinkasserer A. CD83: an update on functions and prospects of the maturation marker of dendritic cells. Arch Dermatol Res 2007, 299:59-69.
32. Kim T.B., Park H.K., Chang J.H., Choi I.H., Kim K.H., Yoon S.J., et al. The establishment of dendritic cell-tumor fusion vaccines for hormone refractory prostate cancer cell. Korean J Urol 2010, 51:139-144.
33. Lee W.T., Tan C., Koski G., Shu S., Cohen P. Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. Head Neck 2010, 32:1209-1216.
34. Zhou J., Weng D., Zhou F., Pan K., Song H., Wang Q., et al. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: invitro results and clinical responses. Cancer Immunol Immunother 2009, 58:1587-1597.
35. De Trizio L., Prato M., Genovese A., Casu A., Povia M., Simonutti R., et al. Strongly fluorescent quaternary Cu-In-Zn-S nanocrystals prepared from Cu1-xInS2 nanocrystals by partial cation exchange. Chem Mater 2012, 24:2400-2406.
36. Szakal A.K., Gieringer R.L., Kosco M.H., Tew J.G. Isolated follicular dendritic cells: cytochemical antigen localization, nomarski, SEM and TEM morphology. JImmunol 1985, 134:1349-1359.
37. Yang L., Ren B., Li H., Yu J., Cao S., Hao X., et al. Cancer Immunol Immun 2013, 62:65-73. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
38. Chan J.K., Hamilton C.A., Cheung M.K., Karimi M., Baker J., Gall J.M., et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 2006, 12:1859-1867.
39. Yamamoto M., Kamigaki T., Yamashita K., Hori Y., Hasegawa H., Kuroda D., et al. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. Oncol Rep 2009, 22:337-343.
40. Lion E., Smits E.L., Berneman Z.N., Van Tendeloo V.F. NK cells: key to success of DC-based cancer vaccines?. Oncologist 2012, 17:1256-1270.
41. Sasaki K., Pardee A.D., Okada H., Storkus W.J. IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. Eur J Immunol 2008, 38:2865-2873.
42. Boe A., Baiocchi M., Carbonatto M., Papoian R., Serlupi-Crescenzi O. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine 1999, 11:1057-1064.
43. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of TH17 cells. Nature 2008, 453:1051-1057.
44. Bettelli E., Oukka M., Kuchroo V.K. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007, 8:345-350.
45. Pinzon-Charry A., Maxwell T., Lopez J.A. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005, 83:451-461.